{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:22:04Z","timestamp":1761060124557},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.mehy.2016.04.037","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T11:55:22Z","timestamp":1461930922000},"page":"57-58","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Systemic anti-CTLA-4 and intravesical Bacille\u2013Calmette\u2013Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?"],"prefix":"10.1016","volume":"92","author":[{"given":"Omar","family":"Fahmy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Ghani","family":"Khairul-Asri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mehy.2016.04.037_b0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.mehy.2016.04.037_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.mehy.2016.04.037_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette\u2013Gu\u00e9rin is superior to a combination of epirubicin and interferon-a2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.mehy.2016.04.037_b0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.mehy.2016.04.037_b0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2013.11.046","article-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines","volume":"65","author":"Witjes","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.mehy.2016.04.037_b0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2012.08.009","article-title":"ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder","volume":"63","author":"Gakis","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.mehy.2016.04.037_b0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11934-015-0532-8","article-title":"Inflammation and cancer: what can we therapeutically expect from checkpoint inhibitors?","volume":"16","author":"Mischinger","year":"2015","journal-title":"Curr Urol Rep"},{"issue":"10","key":"10.1016\/j.mehy.2016.04.037_b0040","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/phar.1643","article-title":"Immune checkpoint inhibitors: new insights and current place in cancer therapy","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.mehy.2016.04.037_b0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2172-9-4","article-title":"Molecular networks discriminating mouse bladder responses to intravesical Bacillus Calmette\u2013Guerin (BCG), LPS, and TNF-alpha","volume":"11","author":"Saban","year":"2008","journal-title":"BMC Immunol"},{"key":"10.1016\/j.mehy.2016.04.037_b0050","series-title":"The elements of immunology","author":"Khan","year":"2009"},{"key":"10.1016\/j.mehy.2016.04.037_b0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette\u2013Gu\u00e9rin","volume":"69","author":"Kamat","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.mehy.2016.04.037_b0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1084\/jem.188.1.205","article-title":"B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28","volume":"188","author":"Fallarino","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.mehy.2016.04.037_b0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/1074-7613(95)90161-2","article-title":"CD28 stimulation can enhance T cell survival by inducing expression of Bcl-xL","volume":"3","author":"Boise","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.mehy.2016.04.037_b0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.mehy.2016.04.037_b0075","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.mehy.2016.04.037_b0080","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.mehy.2016.04.037_b0085","first-page":"931","article-title":"Palliative intralesional interleukin-2 treatment in dogs with urinary bladder and urethral carcinomas","volume":"26","author":"Konietschke","year":"2012","journal-title":"Vivo"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716300561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716300561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T06:53:42Z","timestamp":1600498422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716300561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":17,"alternative-id":["S0306987716300561"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2016.04.037","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic anti-CTLA-4 and intravesical Bacille\u2013Calmette\u2013Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2016.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}